116 related articles for article (PubMed ID: 9840216)
1. Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers.
Demirbas S; Reyderman L; Stavchansky S
Biopharm Drug Dispos; 1998 Nov; 19(8):541-5. PubMed ID: 9840216
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of pseudoephedrine from controlled release formulations in the presence of guaifenesin in human volunteers.
Pade V; Aluri J; Manning L; Stavchansky S
Biopharm Drug Dispos; 1995 Jul; 16(5):381-91. PubMed ID: 8527687
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of dextromethorphan, dextrorphan, and guaifenesin in human plasma using semi-automated liquid/liquid extraction and gradient liquid chromatography tandem mass spectrometry.
Eichhold TH; McCauley-Myers DL; Khambe DA; Thompson GA; Hoke SH
J Pharm Biomed Anal; 2007 Jan; 43(2):586-600. PubMed ID: 16930908
[TBL] [Abstract][Full Text] [Related]
4. Formulation and evaluation of dextromethorphan hydrobromide sustained release tablets.
Meyyanathan SN; Rajan S; Muralidaharan S; Siddaiah MK; Krishnaraj K; Suresh B
Drug Deliv; 2008 Sep; 15(7):429-35. PubMed ID: 18712620
[TBL] [Abstract][Full Text] [Related]
5. Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs.
Kukanich B; Papich MG
J Vet Pharmacol Ther; 2004 Oct; 27(5):337-41. PubMed ID: 15500572
[TBL] [Abstract][Full Text] [Related]
6. Floating matrix dosage form for dextromethorphan hydrobromide based on gas forming technique: in vitro and in vivo evaluation in healthy volunteers.
Hu L; Li L; Yang X; Liu W; Yang J; Jia Y; Shang C; Xu H
Eur J Pharm Sci; 2011 Jan; 42(1-2):99-105. PubMed ID: 21050887
[TBL] [Abstract][Full Text] [Related]
7. Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.
Yeh GC; Tao PL; Ho HO; Lee YJ; Chen JY; Sheu MT
J Biomed Sci; 2003; 10(5):552-64. PubMed ID: 12928596
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous determination of dextrorphan and guaifenesin in human plasma by liquid chromatography with fluorescence detection.
Stavchansky S; Demirbas S; Reyderman L; Chai CK
J Pharm Biomed Anal; 1995 Jun; 13(7):919-25. PubMed ID: 8562617
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.
Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H
Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977
[TBL] [Abstract][Full Text] [Related]
10. [Determination of dextrorphan in human plasma and pharmacokinetic study].
Liu D; Chen XY; Zhang YF; Zhong DF; Gu Q; Zhang Y
Yao Xue Xue Bao; 2004 Jun; 39(6):449-52. PubMed ID: 15491104
[TBL] [Abstract][Full Text] [Related]
11. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability evaluation of a controlled-release dextromethorphan liquid.
Woodworth JR; Dennis SR; Hinsvark ON; Amsel LP; Rotenberg KS
J Clin Pharmacol; 1987 Feb; 27(2):133-8. PubMed ID: 3680564
[TBL] [Abstract][Full Text] [Related]
13. On-line solid phase extraction using the Prospekt-2 coupled with a liquid chromatography/tandem mass spectrometer for the determination of dextromethorphan, dextrorphan and guaifenesin in human plasma.
Kuhlenbeck DL; Eichold TH; Hoke SH; Baker TR; Mensen R; Wehmeyer KR
Eur J Mass Spectrom (Chichester); 2005; 11(2):199-208. PubMed ID: 16046804
[TBL] [Abstract][Full Text] [Related]
14. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of dextromethorphan and its metabolites in horses following a single oral administration.
Corado CR; McKemie DS; Knych HK
Drug Test Anal; 2017 Jun; 9(6):880-887. PubMed ID: 27580591
[TBL] [Abstract][Full Text] [Related]
17. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
[TBL] [Abstract][Full Text] [Related]
18. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
Hu OY; Tang HS; Lane HY; Chang WH; Hu TM
J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
[TBL] [Abstract][Full Text] [Related]
19. Determination of dextromethorphan and dextrorphan in human plasma by liquid chromatography/tandem mass spectrometry.
Eichhold TH; Greenfield LJ; Hoke SH; Wehmeyer KR
J Mass Spectrom; 1997 Nov; 32(11):1205-11. PubMed ID: 9373961
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers.
Silvasti M; Karttunen P; Tukiainen H; Kokkonen P; Hänninen U; Nykänen S
Int J Clin Pharmacol Ther Toxicol; 1987 Sep; 25(9):493-7. PubMed ID: 3679620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
